Konference: 2006 2. ročník Dny diagnostické, prediktivní a experimentální onkologie
Maligní lymfomy a leukémie
Číslo abstraktu: 028p
Autoři: MUDr. Lukáš Smolej, Ph.D.; MUDr. Monika Hrudková; Doc.RNDr. Ctirad Andrýs, Ph.D.; MUDr. David Belada, Ph.D.; Doc.MUDr. Luděk Pour, Ph.D.; Doc. MUDr. Pavel Žák, Ph.D.; Prof. RNDr. Jan Krejsek, CSc.; MUDr. Jakub Novosad, Ph.D.; Prof.MUDr. Jaroslav Malý, CSc.
Increased angiogenesis has been recently reported
in acute and chronic leukemias, lymphomas, and myeloproliferative
disorders. Endoglin (CD105), a member of transforming growth factor
beta (TGFbeta) receptor family, modulates cellular responses to
TGF-beta and is absolutely essential for angiogenesis. Its soluble
form (sCD105) is increased in patients with various solid tumors.
In our pilot study, we measured peripheral blood plasma
concentrations of sCD105 using comercially available enzyme-linked
immunosorbent assay in 75 patients with lymphoid malignancies and
13 healthy donors. We found a statistically significant increase in
sCD105 concentrations in patients with B-cell chronic lymphocytic
leukemia (n = 42) compared to the control group (p = 0.0296).
Suprisingly, patients with multiple myeloma (n = 13) had
significantly lower concentrations of sCD105 in comparison to
controls (p = 0.0023). We didn‘t find significant differences
between sCD105 concentrations in patients with follicular lymphoma
(n = 8) or diffuse large B-cell lymphoma (n = 12) and the control
group. We conclude that plasma sCD105 is a new angiogenesis marker
in lymphoid malignancies and together with other cytokines (such as
VEGF – vascular endothelial growth factor and bFGF – basic
fibroblast growth factor) might be useful as a part of complex
angiogenesis assessment aimed to improve prognostic stratification
of these disorders.
Supported by grants IGA NR/8373-3 and IGA
NR/8076-3 from Ministry of Health of Czech Republic
Datum přednesení příspěvku: 7. 12. 2006